Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03230864 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT03230864 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 119 participants.
The verdict
NCT03230864, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Lu AF35700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2019-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03230864
The ClinicalTrials.gov registry entry for NCT03230864 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT03230864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03230864 about?
NCT03230864 is a clinical study titled "Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia". This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
What is the current status of trial NCT03230864?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2017-07-20. Estimated completion is 2019-02-05.
What interventions are being tested in trial NCT03230864?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Lu AF35700 (DRUG).
Who is sponsoring clinical trial NCT03230864?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.